Bugsee AB

Bugsee AB is a Swedish company developing a nanotechnology-based solution for the rapid isolation of pathogens from whole blood. The technology aims to isolate pathogens in under 30 minutes, a significant improvement over traditional blood culturing methods that can take several days. This macro-to-micro solution is designed for high precision, capable of detecting down to 1 Colony-Forming Unit per milliliter (CFU/mL) while keeping the pathogens 100% viable for subsequent phenotypic analysis.

The company's primary market is in diagnostics for sepsis, a life-threatening condition caused by the body's overwhelming response to a bloodstream infection. Sepsis affects millions of people annually in the EU and US, and rapid diagnosis is critical to preventing septic shock, organ failure, and death. By drastically reducing the time required to isolate pathogens, Bugsee's technology enables faster downstream genotypic and phenotypic testing, allowing for quicker identification of the infection and appropriate antibiotic sensitivity testing. The system is designed as a "plug & play" solution to easily integrate with existing diagnostic technologies.

Keywords: pathogen isolation, sepsis diagnostics, bloodstream infection, nanotechnology, rapid diagnostics, whole blood analysis, phenotypic analysis, antibiotic sensitivity testing, medical technology, in-vitro diagnostics, microbial detection, infectious disease diagnostics